A New Weapon to Fight Neuroblastoma (VIDEO)
Caption
After the first year of receiving the novel treatment combination in the COG trial, 9 out of 17 children with relapsed or resistant neuroblastoma saw either a complete or partial remission -- a 53 percent response rate compared to the typical 10 to 12 percent response rate from chemotherapy or biologic therapy alone.
Credit
University of Michigan Health System
Usage Restrictions
None
License
Licensed content